Menu
X

Jonas Fontenot, Ph.D.

Fontenot
EDUCATION AND TRAINING

Ph.D., Medical Physics, 2008
University of Texas M.D. Anderson Cancer Center / University of Texas-Houston Graduate School of Biomedical Sciences, Houston, TX

M.S., Medical Physics, 2005
University of Texas M.D. Anderson Cancer Center / University of Texas-Houston Graduate School of Biomedical Sciences, Houston, TX

B.S., Physics, 2002
The University of Louisiana-Lafayette, Lafayette, LA

EMPLOYMENT

Chief of Physics, 2015-present
Mary Bird Perkins Cancer Center, Baton Rouge, LA

Academic Medical Physicist, 2008-2015
Mary Bird Perkins Cancer Center, Baton Rouge, LA

CERTIFICATIONS

American Board of Radiology (ABR), 2011
Therapeutic Medical Physics

PUBLICATIONS

1.    Cardenas, J. D. Fontenot, K. Forster, C. Stevens, and G. Starkschall, “Quality assurance evaluation of delivery of respiratory gated treatments,” Journal of Applied Clinical Medical Physics 5, 55-61 (2004).

2.    J. D. Fontenot, W. Newhauser, and U. Titt, “Design Tools for Proton Therapy Nozzles based on the Double-Scattering Foil Technique,” Radiation Protection Dosimetry 116, 211-215 (2005).

3.    J. D. Fontenot, W. Newhauser, C. Bloch, R. A. White, U. Titt, and G. Starkschall, “Determination of output factors for small proton therapy fields,” Medical Physics 34, 489-498 (2007).

4.    Y. Zheng, W. Newhauser, J. D. Fontenot, N. Koch, and R. Mohan, “Monte Carlo simulations of stray neutron radiation exposures in proton therapy,” Journal of Nuclear Materials 361, 289-297 (2007).

5.    W. Newhauser, J. D. Fontenot, N. Koch, L. Dong, A. Lee, Y. Zheng, L. Waters, and R. Mohan, “Monte Carlo simulations of the dosimetric impact of radiopaque fiducial markers for proton radiotherapy of the prostate,” Physics in Medicine and Biology 52, 2937-2952 (2007).

6.    W. Newhauser, N. Koch, J. D. Fontenot, S. Rosenthal, D. Gombos, M. Fitzek, and R. Mohan, “Dosimetric impact of tantalum markers used in the treatment of uveal melanoma with proton beam therapy,” Physics in Medicine and Biology 52, 3979-3990 (2007).

7.    Y. Zheng, W. Newhauser, J. D. Fontenot, P. Taddei, and R. Mohan, “Monte Carlo study of neutron dose equivalent during passive scattering proton therapy,” Physics in Medicine and Biology 52, 4481-4496 (2007).

8.    W. Newhauser, J. D. Fontenot, Y. Zheng, J. Polf, U. Titt, N. Koch, X. Zhang, and R. Mohan, “Monte Carlo simulations for configuring and testing an analytical proton dose-calculation algorithm,” Physics in Medicine and Biology 52, 4569-4584 (2007).

9.    Y. Zheng, J. D. Fontenot, P. Taddei, D. Mirkovic, and W. Newhauser, “Monte Carlo simulations of neutron spectral fluence, radiation weighting factor and ambient dose equivalent for a passively scattered proton therapy unit,” Physics in Medicine in Biology 53, 187-201 (2008).

10.    J. D. Fontenot, P. Taddei, Y. Zheng, D. Mirkovic, T. Jordan, and W. Newhauser, “Equivalent dose and effective dose from stray radiation during passively-scattered proton radiotherapy of the prostate,” Physics in Medicine and Biology 53, 1677-1688 (2008).

11.    P. Taddei, J. D. Fontenot, Y. Zheng, D. Mirkovic, U. Titt, and W. Newhauser, “Modest strategies to reduce stray radiation dose to patients receiving passively-scattered proton radiotherapy for prostate cancer,” Physics in Medicine and Biology 53, 2131-2147 (2008).

12.    Giebeler, J. D. Fontenot, P. Balter, G. Ciangaru, R. Zhu, and W. Newhauser, “Dose perturbations caused by implanted helical gold markers used in patients receiving proton radiation therapy for prostate cancer,” Journal of Applied Clinical Medical Physics 10, 63-70 (2009).

13.    P. Taddei, D. Mirkovic, J. D. Fontenot, A. Giebeler, Y. Zheng, D. Kornguth, R. Mohan, and W. Newhauser, “Stray radiation dose and second cancer risk for a pediatric patient receiving craniospinal irradiation with proton beams,” Physics in Medicine and Biology 54, 2259-2275 (2009).

14.    W. Newhauser, J. D. Fontenot, A. Mahajan, D. Kornguth, M. Stovall, Y. Zheng, P. Taddei, D. Mirkovic, R. Mohan, J. Cox, and S. Woo, “Risk of developing a second cancer after receiving craniospinal proton irradiation,” Physics in Medicine and Biology 54, 2277-2291 (2009).

15.    J. D. Fontenot, A. K. Lee, and W. D. Newhauser, “Risk of secondary malignant neoplasms following proton therapy and intensity modulated x-ray therapy for early stage prostate cancer,” International Journal of Radiation Oncology•Biology•Physics 74 616-622 (2009).

16.    J. D. Fontenot, P. Taddei, Y. Zheng, D. Mirkovic, and W. Newhauser, “Ambient dose equivalent versus effective dose for quantifying stray radiation exposures to a patient receiving proton therapy for prostate cancer,” Nuclear Technology 168 173-177 (2009).

17.    P. Taddei, D. Mirkovic, J. D. Fontenot, A. Giebeler, Y. Zheng, U. Titt, S. Woo, and W. Newhauser, “Reducing stray radiation dose for a pediatric patient receiving proton craniospinal irradiation,” Nuclear Technology 168 108-112 (2009).

18.    J. D. Fontenot, A. K. Lee, and W. D. Newhauser, “Dose-rate effects when estimating risks for second malignancies,” International Journal of Radiation Oncology•Biology•Physics 75 1624-1625 (2009).

19.    M. Ashenafi, R. A. Boyd, T. K. Lee, K. K. Lo, J. P. Gibbons, I. I. Rosen, J. D. Fontenot, and K. R. Hogstrom, “Feasibility of post-mastectomy treatment with helical tomotherapy,” International Journal of Radiation Oncology•Biology•Physics 77 836-842 (2010).

20.    J. D. Fontenot, C. Bloch, D. Followill, U. Titt, and W. D. Newhauser, “Estimate of the uncertainty in relative secondary cancer risk calculations following proton therapy and intensity modulated x-ray therapy,” Physics in Medicine and Biology 55 6987-6998 (2010).

21.    R. Zhang, A. Perez-Andujar, J. D. Fontenot, P. Taddei, and W. D. Newhauser, “Analytic model of stray neutron dose in air and in phantom for proton radiotherapy,” Physics in Medicine and Biology 55 6975-6985 (2010).

22.    S. Ito, B. Parker, R. Levine, M. Sanders, J. D. Fontenot, J. Gibbons, and K. R. Hogstrom, “Verification of calculated skin doses in post-mastectomy helical tomotherapy,” International Journal of Radiation Oncology•Biology•Physics 81 584-591 (2011).

23.    M. Moldovan, J. D. Fontenot, J. Gibbons, T. Lee, I. Rosen, R. Fields, and K. R. Hogstrom, “Investigation of pitch and jaw width to decrease delivery time of helical tomotherapy treatments for head and neck cancer,” Medical Dosimetry 36 397-403 (2011).

24.    J. D. Fontenot, M. King, S. Johnson, C. Wood, M. Price, and K. Lo, “Single-arc volumetric modulated arc therapy can provide dose distributions equivalent to fixed-beam intensity modulated radiation therapy for prostatic irradiation with seminal vesicle and/or lymph node involvement,” at press in The British Journal of Radiology.

25.    O. Blasi, J.D. Fontenot, R. Fields, J. Gibbons, and K. R. Hogstrom, “Preliminary comparison of helical tomotherapy and mixed fields of unmodulated electrons and IMRT for treating superficial head and neck cancers.,” at press in Radiation Oncology.

26.    J. D. Fontenot, “Feasibility of a remote, automated performance-monitoring system for daily delivery of VMAT treatments using a commercial record and verify system,” at press in The Journal of Applied Clinical Medical Physics.

27.    R. Zhang, J. D. Fontenot, D. Mirkovic, J. Hendricks, and W. D. Newhauser, “High speed Monte Carlo dose reconstruction for proton radiation therapy using lattice versus mesh tallies in MCNPX,” submitted to Physics in Medicine and Biology.

28.    J. D. Fontenot, G. Henkelman, C. Wood, R. Levine, K. Lo, and M. King, “Comparison of volumetric modulated arc therapy and helical tomotherapy for hypofractionated radiation therapy of Stage I/II lung cancer,” submitted to Practical Radiation Oncology.